Home > Insider Trading > Filing (0000899243-22-004270)

Filing Details

Accession Number:: 0000899243-22-004270
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-02-02 21:24:03
Reporting Period:: 2022-01-31

Accepted Time:: 2022-02-02 21:24:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1290149	Sierra Oncology Inc.	SRRA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1793762	Joshua Richardson	C/O Sierra Oncology, Inc. 2150 - 885 West Georgia Street Vancouver A1 V6C 3E8		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-02-02	175,000	$27.00	175,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,964,771	Indirect	See footnote

Footnotes

The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright, Juliet Tammenoms Bakker and the Reporting Person, a member of the Issuer's board of directors, are each members of LPF and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP. Each of Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
The securities are held directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and the Reporting Person, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.